Jun 12, 2025 06:01PM
Jun 2, 2025 05:40AM
Jun 2, 2025 01:25AM
Feb 28, 2025 08:00AM
Feb 20, 2025 09:32AM
Dec 7, 2024 12:30PM
Aug 1, 2024 07:00AM Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
May 30, 2024 06:01PM
May 23, 2024 05:05PM
May 2, 2024 07:00AM
Feb 23, 2024 08:01AM
Feb 23, 2024 08:00AM
Feb 22, 2024 07:51AM
Dec 9, 2023 12:30PM Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
Aug 2, 2023 07:00AM
May 23, 2023 10:00AM
May 23, 2023 10:00AM
May 22, 2023 04:05PM
May 22, 2023 04:04PM
May 4, 2023 07:00AM
Mar 28, 2023 04:06PM Blueprint Medicines (BPMC) says FDA lifts partial clinical hold on BLU-222
Mar 28, 2023 04:05PM
Feb 26, 2023 03:00PM
Feb 23, 2023 08:01AM
Feb 23, 2023 08:00AM
Feb 16, 2023 07:00AM
Feb 10, 2023 08:00AM
Feb 10, 2023 08:00AM Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
Feb 3, 2023 09:00AM
Jan 23, 2023 08:01AM
Jan 23, 2023 08:00AM
Jan 5, 2023 08:06AM
Jan 5, 2023 08:00AM
Dec 11, 2022 05:30PM
Nov 22, 2022 04:37PM Blueprint Medicines (BPMC) Submits sNDA to FDA for AYVAKIT for Treatment of Indolent Systemic Mastocytosis
Nov 22, 2022 04:36PM
Nov 1, 2022 08:00AM
Aug 17, 2022 07:08AM
Aug 17, 2022 07:00AM
Aug 2, 2022 07:00AM
Jun 30, 2022 07:16AM
Jun 30, 2022 07:15AM Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
Jun 9, 2022 07:07AM
Jun 9, 2022 07:00AM
May 3, 2022 07:00AM
Mar 25, 2022 10:15AM
Feb 16, 2022 07:00AM
Jan 28, 2022 08:01AM
Jan 28, 2022 08:00AM Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
Jan 10, 2022 08:16AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All